Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer

Prostate

Volumn 47, Issue 3, 2001, Pages 222-229

  McNeel, Douglas G ^a   Nguyen, Lan D ^b   Ellis, William J ^b   Higano, Celestia S ^b   Lange, Paul H ^b   Disis, Mary L ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Helper T cells; IL 5; Interferon gamma; Prostate cancer; Prostate specific antigen; Th1 cells

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 5; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY;

ACID PHOSPHATASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PHENOTYPE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TH1 CELLS;

EID: 0035873903     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1066     Document Type: Article

References (42)

1. The immune system as anti-tumor sentinel: Molecular requirements for an anti-tumor immune response
2. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
3. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory
4. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization; implications for immunotherapy of prostate cancer
5. Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: Implications for prostate cancer therapy
6. Experimental autoimmune damage to rat male accessory glands. II. T cell requirement in adoptive transfer of specific tissue damage
7. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide
8. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
9. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
10. The central role of CD4(+) T cells in the antitumor immune response
11. CD4 T cells and their role in antitumor immune responses
12. The role of CD4+ T cell responses in antitumor immunity
13. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
14. T helper cells in immune mice amplify the primary anti-tumor cytotoxic response
15. IFN-gamma-secreting Th cells regulate both the frequency and avidity of epitope-specific CD8+ T lymphocytes induced by peptide immunization: An ex vivo analysis
16. Cytotoxic T cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells
17. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
18. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
19. The expanding universe of T cell subsets: Th1, Th2 and more
20. IL-12 induces T helper 1-directed antitumor response
21. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice
22. Redirecting Th1 and Th2 responses in autoimmune disease
23. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant
24. T cell subsets in autoimmunity
25. Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas
26. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas
27. Immunotherapy of advanced prostate cancer: A phase I/II trial using Mycobacterium vaccae (SRL172)
28. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients
29. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer
30. Tumor vaccines for the management of prostate cancer
31. Presentation of prostate tumor antigens by dendritic cells stimulates T cell proliferation and cytotoxicity
32. Identification of HLA-A2-restricted T cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
33. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: Helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro
34. Definition of tumor antigens suitable for vaccine construction
35. Human tumor antigens recognized by T cells
36. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome
37. Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer
38. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
39. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
40. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
41. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
42. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment